Incannex Healthcare Inc., a clinical-stage biopharmaceutical company, engages in the research and development of psychedelic medicines and therapies for patients with chronic diseases in Australia. The company develops IHL-42X, an oral fixed dose combination of dronabinol and acetazolamide that is in Phase 2/3 clinical trial for the treatment of obstructive sleep apnea; and PSX-001, an oral synthetic psilocybin treatment in Phase 2b clinical development for patients with generalized anxiety disorder. It is developing IHL-675A, an oral fixed dose combination drug containing synthetic cannabidiol and hydroxychloroquine sulphate to treat rheumatoid arthritis, as well as lung inflammation, acute respiratory disease, chronic obstructive pulmonary disease, asthma, bronchitis, inflammatory bowel disease, colitis, and Crohn's disease. The company is headquartered in Melbourne, Australia.…
Stonegate Updates Coverage on Incannex Healthcare Inc. (IXHL) FY26
Incannex Healthcare (NASDAQ: IXHL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 12 employees.
The shares were at 1.860 USD on 20 November 2026, down 83.4% over 52 weeks. Its 52-week range is 1.610 USD to 14.91 USD: the price is 87.5% below the high and 15.5% above the low.
Its market capitalisation is 23.34M USD.
Incannex Healthcare reports return on equity of -28.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 67.61M USD. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health.